Skyzoster (live attenuated zoster vaccine) / SK Bio - LARVOL DELTA

Post-marketing Surveillance of a Live Attenuated Herpes Zoster Vaccine (SKYZoster®) in Adults Aged ≥50 Years in Korea. (PubMed, Infect Chemother) - "Over a 4-year post-marketing safety evaluation period, SKYZoster exhibited an acceptable safety profile in routine clinical practice in Korea. The vaccine was well-tolerated, with no serious adverse event reported, reaffirming its role in preventing HZ in adults."

Journal • P4 data • Allergy • Dermatology • Herpes Zoster • Immunology • Infectious Disease • Pain • Pruritus • Varicella Zoster

Immunogenicity and Safety of a Newly Developed Live Attenuated Varicella Vaccine in Healthy Children: A Multi-National, Randomized, Double-Blinded, Active-Controlled, Phase 3 Study. (PubMed, Vaccines (Basel)) - "There were no significant differences between the NBP608 and control group with respect to the proportions of participants who demonstrated local and systemic solicited AEs. This study indicated that NBP608 had a clinically acceptable safety profile and was not immunologically inferior to Varivax."

Clinical • Journal • P3 data • Varicella Zoster

Turkey renews SK Bioscience’s vaccine manufacturing certification (The Korea Herald) - "SK Bioscience, the vaccine unit of Korea’s SK Group, said Friday the Turkish health authority has renewed a certification for making and exporting vaccines for flu, chickenpox and shingles, paving the way for the company to participate in a vaccine deal bid in Turkey...In the facility, flu vaccine SKYcellflu Trivalent and Quadrivalent, chickenpox vaccine SKYvaricella and the vaccine for herpes zoster, also known as shingles, called Skyzoster are manufactured, the company said."

Commercial • Herpes Zoster • Infectious Disease